Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Newton, MA, US. The stock last traded at $2.47, up 1.65% on the session, giving a market capitalisation of $178.4M. On trailing twelve-month figures it carries a trailing P/E of -1.50, a net margin of -114178.3%. Its beta of 0.33 implies it has historically moved less than the broad market.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc. is most often compared with the following Healthcare names: